Celularity EBIT/Varat

Mitä Celularity tekee? Celularity Inc, listed on the stock market with ticker CELU and ISIN US1511902041, is a biotechnology company headquartered in Florham Park, New Jersey, United States. The company operates within the Health Care sector, specifically in the Biotechnology industry. Celularity has 225 employees and completed its initial public offering (IPO) on May 23, 2019. The company focuses on developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune disorders, and infectious diseases. Its research and development efforts include various therapy product candidates such as T cells engineered with a chimeric antigen receptor (CAR), natural killer cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target a range of conditions including cancer, infectious diseases, and degenerative diseases. Celularity's product pipeline features several programs, including CYCART-19, which is a placental-derived CAR-T cell therapy targeting B-cell malignancies, and pEXO-001, among others. The company's operations are structured around three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Celularity's website is https://celularity.com/. Celularity on yksi Eurpooliin suosituimmista yhtiöistä.